Items where authors include "Kaiser, M"

Article

Hayward, CJ orcid.org/0000-0001-5563-8296, Huo, S, Chen, X et al. (1 more author) (2023) Nonoptimal component placement of the human connectome supports variable brain dynamics. Network Neuroscience, 7 (1). pp. 254-268. ISSN 2472-1751

Royle, K-L orcid.org/0000-0003-0225-1199, Coulson, AB, Ramasamy, K et al. (26 more authors) (2022) Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial. BMJ Open, 12 (11). e063037. ISSN 2044-6055

Coulson, AB, Royle, K-L orcid.org/0000-0003-0225-1199, Pawlyn, C et al. (22 more authors) (2022) Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open, 12 (6). e056147. ISSN 2044-6055

Caro, J, Cairns, D orcid.org/0000-0002-2338-0179, Menzies, T orcid.org/0000-0003-3896-7228 et al. (11 more authors) (2022) Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 22 (4). E279-E284. ISSN 2152-2650

Pawlyn, C, Cairns, D orcid.org/0000-0002-2338-0179, Menzies, T orcid.org/0000-0003-3896-7228 et al. (11 more authors) (2022) Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. Haematologica, 107 (1). pp. 231-242. ISSN 0390-6078

Bird, S, Cairns, D orcid.org/0000-0002-2338-0179, Menzies, T orcid.org/0000-0003-3896-7228 et al. (12 more authors) (2021) Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clinical Lymphoma Myeloma and Leukemia, 21 (10). pp. 667-675. ISSN 2152-2650

Bygrave, C, Pawlyn, C, Davies, F et al. (11 more authors) (2021) Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma. British Journal of Haematology, 193 (3). pp. 551-555. ISSN 0007-1048

Moreau, P, Kumar, SK, San Miguel, J et al. (67 more authors) (2021) Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. The Lancet Oncology, 22 (3). e105-e118. ISSN 1470-2045

Terpos, E, Mikhael, J, Hajek, R et al. (13 more authors) (2021) Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal, 11 (2). 40. ISSN 2044-5385

Hoang, PH, Cornish, AJ, Sherborne, AL et al. (8 more authors) (2020) An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics. Blood Cancer Journal, 10 (10). 101. ISSN 2044-5385

Cook, G orcid.org/0000-0003-0223-3652, Ashcroft, AJ, Pratt, G et al. (13 more authors) (2020) Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with Multiple Myeloma receiving systemic anti‐cancer therapy. British Journal of Haematology. ISSN 0007-1048

Pawlyn, C, Cairns, D orcid.org/0000-0002-2338-0179, Kaiser, M et al. (11 more authors) (2020) The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia, 34 (2). pp. 604-612. ISSN 0887-6924

Dimopoulos, MA, Gay, F, Schjesvold, F et al. (24 more authors) (2019) Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet, 393 (10168). pp. 253-264. ISSN 0140-6736

Kaiser, M, Burek, M, Britz, S et al. (6 more authors) (2019) The influence of capsaicin on the integrity of microvascular endothelial cell monolayers. International Journal of Molecular Sciences, 20 (1). 122. ISSN 1661-6596

Heaney, JLJ, Campbell, JP, Iqbal, G et al. (11 more authors) (2018) Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia, 32 (8). pp. 1727-1738. ISSN 0887-6924

Ludwig, H, Delforge, M, Facon, T et al. (29 more authors) (2018) Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 32 (7). pp. 1542-1560. ISSN 0887-6924

Mengoni, T, Adrian, M, Pereira, S et al. (3 more authors) (2017) A chitosan-based liposome formulation enhances the in vitro wound healing efficacy of substance P neuropeptide. Pharmaceutics, 9 (4). 56. ISSN 1999-4923

Campbell, JP, Heaney, JLJ, Pandya, S et al. (10 more authors) (2017) Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. Lancet Haematology. ISSN 2352-3026

Kaiser, M, Pohl, L, Ketelhut, S et al. (6 more authors) (2017) Nanoencapsulated capsaicin changes migration behavior and morphology of madin darby canine kidney cell monolayers. PLOS ONE, 12 (11). e0187497.

Campbell, JP, Heaney, JLJ, Pandya, S et al. (9 more authors) (2017) Active multiple myeloma suppresses and typically eliminates coexisting MGUS. British Journal of Cancer, 117 (6). pp. 835-839. ISSN 0007-0920

Datta, D, Pohlentz, G, Schulte, M et al. (5 more authors) (2016) Physico-chemical characteristics and primary structure of an affinity-purified α-D-galactose-specific, jacalin-related lectin from the latex of mulberry (Morus indica). Archives of Biochemistry and Biophysics, 609. pp. 59-68. ISSN 0003-9861

Mitchell, JS, Li, N, Weinhold, N et al. (55 more authors) (2016) Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nature Communications, 7. 12050.

Brown, S, Hinsley, S orcid.org/0000-0001-6903-4688, Ballesteros, M et al. (11 more authors) (2016) The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. BMC hematology, 16. p. 14. ISSN 2052-1839

Johnson, DC, Weinhold, N, Mitchell, J et al. (18 more authors) (2016) Genetic factors influencing the risk of multiple myeloma bone disease. Leukemia, 30 (4). pp. 883-888. ISSN 0887-6924

Kaiser, M, Chalapala, S, Gorzelanny, C et al. (2 more authors) (2016) The Effect of Capsaicin Derivatives on Tight-Junction Integrity and Permeability of Madin-Darby Canine Kidney Cells. Journal of Pharmaceutical Sciences, 105 (2). pp. 630-638. ISSN 0022-3549

Johnson, DC, Weinhold, N, Mitchell, JS et al. (19 more authors) (2016) Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. Nature Communications, 7. 10290.

Kaiser, M, Kirsch, B, Hauser, H et al. (3 more authors) (2015) In Vitro and Sensory Evaluation of Capsaicin-Loaded Nanoformulations. PLOS ONE. e0141017.

Kaiser, M, Pereira, S, Pohl, L et al. (6 more authors) (2015) Chitosan encapsulation modulates the effect of capsaicin on the tight junctions of MDCK cells. Scientific Reports, 5. 10048. ISSN 2045-2322

Mitchell, JS, Johnson, DC, Litchfield, K et al. (8 more authors) (2015) Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. Scientific Reports, 5. 12473. ISSN 2045-2322

Proceedings Paper

Shah, V, Johnson, DC, Sherborne, AL et al. (18 more authors) (2018) Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials. In: Blood. 60th ASH Annual Meeting, 01-04 Dec 2018, San Diego, California, USA. American Society of Hematology , p. 2000.

Croft, J, Hall, A, Walker, K et al. (11 more authors) (2018) Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone. In: Blood. ASH 2018 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology , p. 4482.

Bygrave, CA, Pawlyn, C, Davies, FE et al. (19 more authors) (2018) Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial. In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .

Jackson, GH, Davies, FE, Pawlyn, C et al. (18 more authors) (2018) A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study. In: Blood. 60th ASH Annual Meeting, 01-04 Dec 2018, San DIego, California, USA. American Society of Hematology , p. 302.